ClinicalTrials.gg
CompletedNCT02097043Updated Dec 26, 2019

Phase I Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of DA-7218 in Healthy Male Volunteers

A Phase 1 interventional study of DA-7218 and Placebo in Healthy, sponsored by Dong-A ST Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-26.

Sponsored by Dong-A ST Co., Ltd. · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
19 Years to 45 Years
Sex
Male
01

Study summary

This study is a phase I clinical trial for evaluating the pharmacokinetics and safety/tolerability of DA-7218 in healthy male volunteers.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Dong-A ST Co., Ltd. is the lead sponsor of 122 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male Korean 19-45 years
  • Body weight:55-90kg, :18.0-27.0

Exclusion criteria

Exclusion Criteria:

  • Present condition or history of any disease
  • Clinical evidence or history of GI disease or history of GI surgery
  • History of , including drug allergies
  • (SGOT) or ALT (SGPT) > 1.5 times the upper normal limit
  • Systolic blood pressure : \<100 mmHg or >160 mmHg
  • Diastolic blood pressure : \<60 mmHg or >100 mmHg
  • Drug abuse within 2 months, or a positive reaction to an abusive drug or cotinine
  • Taken any ETC or herbal supplement within 2 weeks or any OTC or vitamin supplement within 1 week
  • Participation in and administration of IP of another clinical trial within 2 months
  • Donation of whole blood within 2 months, or blood components within 1 month, or receipt of blood transfusion within 1 month
  • Consumption of more than 21 units of alcohol/week or inability to abstain from drinking during the study period
  • Smoking within 3 months
  • Taking caffeine- or grapefruit-containing products within 3 days
  • Plan to be pregnant, or not to use an appropriate method of
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    [Group 1] DA-7218

    200mg, By mouth or orally (PO) \& intravenous(IV) administration

    Drug: DA-7218

  • Placebo comparator
    [Group 1] Placebo

    Placebo, By mouth or orally (PO) \& intravenous(IV) administration

    Drug: Placebo

  • Experimental
    [Group 2] DA-7218

    400mg, By mouth or orally (PO) administration

    Drug: DA-7218

  • Placebo comparator
    [Group 2] Placebo

    Placebo, By mouth or orally (PO) administration

    Drug: Placebo

  • Experimental
    [Group 3] DA-7218

    600mg, By mouth or orally (PO) administration

    Drug: DA-7218

  • Placebo comparator
    [Group 3] Placebo

    Placebo, By mouth or orally (PO) administration

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. AUClast

    Area under the concentration-time curve from time zero to the last quantifiable concentration by linear trapezoidal method

    Time frame: 72 hours

  2. Cmax

    Time frame: 72 hours

Secondary outcomes

  1. tmax, AUCinf, t1/2, CL/F, Vz/F (F; calculated in group 1)

    Time frame: 72 hours

Other outcomes

  1. Adverse events (subjective or objective symptoms)

    Time frame: 14 days(group 1), 7 days(group 2,3)

  2. Vital signs

    Time frame: 14 days(group 1), 7 days(group 2,3)

  3. Physical examination

    Time frame: 14 days(group 1), 7 days(group 2,3)

  4. 12-lead ECG

    Time frame: 14 days(group 1), 7 days(group 2,3)

  5. Clinical laboratory tests

    Time frame: 14 days(group 1), 7 days(group 2,3)

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, Korea, Republic of
08

References and documents

Publications

  • Kim Y, Kim A, Lee S, Choi SH, Lee DY, Song JS, Lee H, Jang IJ, Yu KS. Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate After Single-dose Administration in Healthy Korean Male Subjects. Clin Ther. 2017 Sep;39(9):1849-1857. doi: 10.1016/j.clinthera.2017.08.002. Epub 2017 Aug 31. PubMed 28865799 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2014, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2014
First posted
Mar 26, 2014
Start
May 2014
Primary completionActual
May 2014
CompletionActual
May 2014
Last update
Dec 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02097043
Responsible party
Sponsor
First posted
Mar 26, 2014
Start date
May 2014
Primary completion
May 2014
Completion
May 2014
Last update
Dec 26, 2019

Study contacts

Kyung Sang Yu, M.D., Ph.D.
principal investigator · Seoul National University College of Medicine / Seoul National University Hospital
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tedizolid phosphate

Start the discussion